Announcements Trials

Browse Landscape

Phase

Status

Unknown 7 Completed 2 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 22 Gastrointestinal 8 Head & Neck 5 Sarcoma 3 Gynecologic 3 Breast 3 Tumor-Agnostic 2 Genitourinary 2 Endocrine 1 Dermatologic 1 CNS 1

Conditions

Brain Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Temozolomide 20 Magnetic Resonance Spectroscopy 10 Radiotherapy 9 Blood Specimen Collection 8 pembrolizumab 6 Cyclophosphamide 6 Bevacizumab 6 AZD 6244 6 Radiation 5 Specimen Handling 4 vorasidenib 3 fludarabine 3 cemiplimab 3 aflutinib 3 Surgical Procedures, Operative 3 Saline Solution 3 Radiotherapy, Intensity-Modulated 3 Radiosurgery 3 Pemetrexed 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 tislelizumab 2 osimertinib 2 naxitamab 2 gallium maltolate 2 fludarabine phosphate 2 dinutuximab 2 Topotecan 2 Standard of Care 2 Spinal Puncture 2 Receptors, Interleukin-8B 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × anlotinib × CNS × Clear all

NCT06483672 2024-07-03

LungBrain001

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting

Adenocarcinoma of Lung, Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡